taPentadol cLinical prAcTice IN belgiUM

Severe Pain Syndromes Clinical Trial

— PLATINUM  

Official title:

Multicenter Observational Study to Determine the Long-term Tolerability and Analgesic Effectiveness of Oral Tapentadol in Patients Suffering From Severe Pain Syndromes, Refractory to Other Strong Opioids.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03814993
• Other study ID #: PLATINUM
• Status: Completed
• Start date: July 29, 2019
• Est. completion date: August 1, 2021

Study information

• Verified date: February 2022
• Source: University Hospital, Antwerp
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Multicenter observational study to determine the long-term tolerability and analgesic effectiveness of oral tapentadol in patients suffering from severe pain syndromes, refractory to other strong opioids.

Description:

Tapentadol, a centrally acting analgesic. It is indicated in Europe "for the relief of moderate to severe acute pain in adults, which can be adequately managed only with opioid analgesics" (IR formulation/oral solution) and "for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics" (SR formulation). Tapentadol is reimbursed in Belgium since May 1, 2018. The reimbursement was obtained through an article 81 procedure (Chapter IV) which means that the reimbursement is currently restricted to the time frame of the contract and that during that period certain questions and uncertainties regarding the use of tapentadol in a Belgian setting need to be answered. In order to answer the questions raised by the Belgian Healthcare authorities, this study will be performed evaluating the application of oral tapentadol in routine clinical practice in Belgium. The study is conceived as a nation-wide multicentre prospective non-interventional trial. The primary endpoint and secondary endpoints of this study are guided by the questions that need to be answered during the course of the contract reimbursement, as established by the Belgian health authorities.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: August 1, 2021
• Est. primary completion date: August 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects should be capable of giving their informed consent;

• Males and females, 18 years and older;

• Patients suffering from severe pain;

• Pain symptoms refractory to strong opioids (in previous treatment);

• Due to side effects

• Due to insufficient analgesic effectiveness

• Due to opioid induced hyperalgesia.

Exclusion Criteria:

• Severe renal and/or hepatic insufficiency;

• Known and/or strong suspicion of allergy to tapentadol;

• Previous treatment with tapentadol;

• Presence of any condition for which tapentadol is contraindicated as per its approved labelling information in Belgium;

• The patient has no access to a mobile phone and web browser. During the study, an online system is used to receive messages (SMS and e-mail) for the completing of the online assessments (through web browser).

Related Conditions & MeSH terms

• Severe Pain Syndromes
• Syndrome

Locations

Country	Name	City	State
Belgium	AZ Monic	Antwerp
Belgium	University Hospital Antwerp	Antwerp
Belgium	Huisartspraktijk Van Peer	Boechout
Belgium	Ziekenhuis Oost-Limburg	Genk
Belgium	Jessa Ziekenhuis Hasselt	Hasselt
Belgium	AZ Groeninge	Kortrijk
Belgium	UZ Leuven	Leuven
Belgium	CHU Liège (Sart Tilman)	Liège
Belgium	Huisartspraktijk De Vaart	Mechelen
Belgium	Grand Hôpital Charleroi	Montignies-sur-Sambre
Belgium	AZ Turnhout	Turnhout

Sponsors (2)

Lead Sponsor	Collaborator
Dafne Balemans	Grünenthal GmbH

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in occurrence of gastrointestinal side effects (nausea, vomiting and constipation) between baseline and week 15	Differences in occurence of the PRO-CTCAE items: Nausea, vomiting and constipation	baseline - week 15
Secondary	Difference in frequency, severity and interference of selected side effects (dizziness, fatigue, itching, headache, dry mouth, nausea, vomiting, constipation) from baseline to week 52	Difference in frequency, severity and interference of selected PRO-CTCAE items	baseline - week 52
Secondary	Change From Baseline in Pain Scores on the Numeric Rating Scale baseline to different time points during long-term follow-up	Reduction in pain intensity numeric rating scale (PI-NRS). Scale: 0 = no pain and 10 = worst possible pain	baseline - week 52
Secondary	Change of health-related quality of life from baseline to different time points during long-term follow-up	Change of healt-related quality of life measured by EQ-5D-5L (monthly evaluation)	baseline - week 52
Secondary	Change of health-related quality of life from baseline to different time points during long-term follow-up	Change of healt-related quality of life measured SF-36 (monthly evaluation)	baseline - week 52
Secondary	Change of functional status of the patient from baseline to different time points during long-term follow-up	Change of functional status measured by GPE-DV (monthly evaluation)	baseline - week 52
Secondary	Change of functional status of the patient from baseline to different time points during long-term follow-up	Change of functional status measured by impact pain on functioning (Interference-BPI)	baseline - week 52
Secondary	Change of functional status of the patient from baseline to different time points during long-term follow-up	Change of functional status measured by SF-36 (monthly evaluation)	baseline - week 52
Secondary	The occurrence of tolerance during oral tapentadol treatment from baseline to different time points during long-term follow-up	Occurence of tolerance by the use of MQS-III questionnaire (weekly or monthly)	baseline - week 52
Secondary	The occurrence of tolerance during oral tapentadol treatment from baseline to different time points during long-term follow-up	Occurence of tolerance by the use time-point of discontinuation of study drug	baseline - week 52
Secondary	Drug conversion rates from other strong opioids to oral tapentadol from baseline to different time points during long-term follow-up	By the use of MQS-III questionnaire	baseline - week 52